Navigation Links
Part I. Not for release, publication or distribution, in whole or in part, directly or indirectly, in, into or from any jurisdiction where to do so would constitute a violation of the relevant laws or regulations of such jurisdiction.
Date:7/18/2014

NORTH CHICAGO, Ill., July 18, 2014 /PRNewswire/ --

Summary

  • The Boards of AbbVie and Shire are pleased to announce that they have reached agreement on the terms of a recommended combination of Shire with AbbVie.
  • Under the terms of the Merger, Shire Shareholders will be entitled to receive: for each Shire Share:  £24.44 in cash and 0.8960 New AbbVie Shares
  • The Merger terms represent:
  • An indicative value of £52.48 per Shire Share based on AbbVie's closing share price of $53.52 on 17 July 2014, the Latest Practicable Date; and
  • An indicative value of £53.19 per Shire Share based on AbbVie's 30-day volume-weighted average price of $54.83 to 17 July 2014, the Latest Practicable Date.
  • The indicative value of £53.19 per Shire Share values the entire issued and to be issued share capital of Shire on a fully diluted basis at approximately £32 billion and represents:
  • A premium of approximately 53 per cent. to the price of Shire Shares of £34.67 on 2 May 2014, being the last Business Day prior to AbbVie's initial proposal;
  • A premium of approximately 42 per cent. to the price of Shire Shares of £37.38 on 19 June 2014, being the last Business Day prior to the commencement of the offer period; and
  • An implied Enterprise Value / Last Twelve Months EBITDA multiple of approximately 24x.
  • The Transaction will create a well-positioned and focused specialty biopharmaceutical company, with sustainable leadership positions within areas of unmet need, including immunology, rare diseases, neuroscience, metabolic diseases and liver disease (HCV) and multiple emerging oncology programs.
  • Immediately following the Transaction, Shire Shareholders are expected to hold New AbbVie Shares representing approximately 25 per cent. of the issued share capital of New AbbVie, thus offering Shire Shareholders the ability to participate in the future prosp
    '/>"/>

  • SOURCE AbbVie Inc.
    Copyright©2014 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

    Related medicine technology :

    1. North American Drug Delivery Technologies Market (Metered Dose Inhalers, Needle-Free Injectors, Auto-Injectors, Nasal Sprays, Transdermal Patches, Nebulizers, Infusion Pumps, Drug Eluting Stents, Sustained Release, Ocular Implants) - Forecasts To 20
    2. aTyr Pharma Announces Publication of a Rare Muscle Disease Associated with Regulation of a Potential Physiocrine
    3. BioLineRx Reports Publication in Peer Review Journal of Positive Phase 1/2 Results in Stem Cell Mobilization for Multiple Myeloma
    4. Micell Technologies Announces DESSOLVE I Manuscript Accepted for Publication in American College of Cardiologys Cardiovascular Interventions Journal
    5. Avanir Pharmaceuticals Announces Publication of AVP-825 Pharmacokinetic Data in Journal "Headache"
    6. Avanir Pharmaceuticals Announces Publication of PRISM Pseudobulbar Affect Registry Findings
    7. BioLineRx Announces Publication of Positive Pre-Clinical Results for BL-8040 in Treatment of Thrombocytopenia
    8. Sangamo BioSciences Announces Publication of First Demonstration of Inactivation of Extra Chromosome Responsible for Down Syndrome
    9. SI-BONE, Inc. Announces Publication of Postmarket Surveillance Safety Data on First 5,319 Patients Treated with iFuse Implant System
    10. Metabolic Solutions Development Company announces publication of data describing potential for new drugs to maintain pancreatic beta-cells in treating diabetes
    11. Sanofi and Regeneron Announce Publication of Positive Phase 2a Results of Dupilumab in Asthma in the New England Journal of Medicine
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/30/2014)... -- , Extensively hydrolyzed milk formula with LGG ... Cow milk protein allergy (CMPA) is the leading cause of food ... has been managed by eliminating milk proteins from a ... is possible to help build of oral tolerance to ... the first year of life by using an extensively ...
    (Date:10/30/2014)... , Oct. 29, 2014 nebulizer is a ... (asthma, COPD and cystic fibrosis) that converts liquid medication ... reach into the lungs of a patient when inhaled ... nebulizers market is dominated by various devices powered by ... prevalence of asthma, COPD and cystic fibrosis and growing ...
    (Date:10/30/2014)... LOS ANGELES , Oct. 29, 2014 /PRNewswire/ ... pharmaceutical company devoted to bringing new products to ... 2015. ViaDerma has developed an innovative, ... for rapid mass transfer of pharmaceutical active ingredients ... to provide immediate localized therapy. The transdermal delivery ...
    Breaking Medicine Technology:Experts Present Latest Research at Allergy Day 2Experts Present Latest Research at Allergy Day 3Nebulizers Market (Pneumatic Nebulizers, Ultrasonic Nebulizers and Mesh Nebulizers) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019 2Nebulizers Market (Pneumatic Nebulizers, Ultrasonic Nebulizers and Mesh Nebulizers) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019 3ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 2ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 3
    ... at American College of Rheumatology Annual Congress -, ... BMY ) today announced the results of ... that showed ORENCIA(R) (abatacept) improved daily,activity participation, such ... and sleep quality in adult rheumatoid arthritis,(RA) patients ...
    ... Ophthalmology Annual Meeting Describes ... in Treatment of Endothelial Disease, NEW ORLEANS, Nov. ... Academy of Ophthalmology,s Annual Meeting, Massimo Busin,MD, department head ... Italy, described a technique that significantly improved,results in patients ...
    Cached Medicine Technology:Post-Hoc Data Show Daily Activity Participation, Independence and Sleep Quality Improved in Adults with Moderate to Severe Rheumatoid Arthritis After Treatment with ORENCIA(R) (Abatacept) 2Post-Hoc Data Show Daily Activity Participation, Independence and Sleep Quality Improved in Adults with Moderate to Severe Rheumatoid Arthritis After Treatment with ORENCIA(R) (Abatacept) 3Post-Hoc Data Show Daily Activity Participation, Independence and Sleep Quality Improved in Adults with Moderate to Severe Rheumatoid Arthritis After Treatment with ORENCIA(R) (Abatacept) 4Post-Hoc Data Show Daily Activity Participation, Independence and Sleep Quality Improved in Adults with Moderate to Severe Rheumatoid Arthritis After Treatment with ORENCIA(R) (Abatacept) 5Post-Hoc Data Show Daily Activity Participation, Independence and Sleep Quality Improved in Adults with Moderate to Severe Rheumatoid Arthritis After Treatment with ORENCIA(R) (Abatacept) 6Post-Hoc Data Show Daily Activity Participation, Independence and Sleep Quality Improved in Adults with Moderate to Severe Rheumatoid Arthritis After Treatment with ORENCIA(R) (Abatacept) 7Post-Hoc Data Show Daily Activity Participation, Independence and Sleep Quality Improved in Adults with Moderate to Severe Rheumatoid Arthritis After Treatment with ORENCIA(R) (Abatacept) 8Post-Hoc Data Show Daily Activity Participation, Independence and Sleep Quality Improved in Adults with Moderate to Severe Rheumatoid Arthritis After Treatment with ORENCIA(R) (Abatacept) 9Improved Cornea Surgery Technique Provides Enhanced Transplant Success 2
    (Date:10/30/2014)... Graphics, coding, typography and search engine optimization– ... of web design and require thorough knowledge to create ... to create a website can be as easy as ... reviews and Facebook posts all accumulate on a multiple ... evolution of how a business can develop a website," ...
    (Date:10/30/2014)... (PRWEB) October 30, 2014 Paramount Rx, ... care, is increasing efforts to help people save money ... continue to increase for prescription drugs in the new ... savings and resources to bridge the relationship between consumers, ... of the biggest challenges people face today with medical ...
    (Date:10/30/2014)... 2014 Home Care Assistance – Halton/Peel ... non-medical, in-home senior care, is weighing in on a ... , The study, performed by the University of Illinois, ... 78 over a week-long period and observed how much ... activity. By examining the structural soundness of the white ...
    (Date:10/30/2014)... Newport Beach, California (PRWEB) October 30, 2014 ... superfood nutrtion bars are now available through a unique ... an online site designed to empower the everyday athlete. ... the worlds best athletes and created a system to ... really excited to see REV’D® is now available on ...
    (Date:10/30/2014)... 2014 (HealthDay News) -- When it comes to heart disease, ... to delay care when they have symptoms that spell trouble. ... the hospital with a more severe or advanced stage of ... author Catherine Kreatsoulas, a Fulbright Scholar and research fellow at ... release from the Heart and Stroke Foundation of Canada. ...
    Breaking Medicine News(10 mins):Health News:Facebook Websites In Thirty-Seconds 2Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 2Health News:Paramount Rx Discount Card Program Provides Valuable Resources in Midst of Current Health Care Reform 3Health News:Home Care Assistance – Halton/Peel Region, a Top Provider of In-Home Care, Responds to Study Linking Exercise to Healthier Senior Brains 2Health News:Home Care Assistance – Halton/Peel Region, a Top Provider of In-Home Care, Responds to Study Linking Exercise to Healthier Senior Brains 3Health News:Nutrition Experts at TheFeed.com Get REV'D 2Health News:Nutrition Experts at TheFeed.com Get REV'D 3Health News:Women Often Ignore Signs of Heart Trouble 2
    ... action for the public, health professionals, the food industry and ... sodium (salt) Americans consume daily. , In an advisory, ... , the association sets out the science behind the American ... consume no more than 1500 milligrams (mg) of sodium a ...
    ... HealthDay Reporter , THURSDAY, Jan. 13 (HealthDay News) -- ... "Together We Thrive: Tucson and America" memorial, President Barack Obama ... visit with her and her husband Mark Kelly at University ... An aide to House Minority Leader Nancy Pelosi (D-Calif.) ...
    ... plenty of natural light and artwork may seem like unaffordable ... and design features can improve patient care and in the ... elements of the "Fable hospital," an ideal health care facility ... design. Elements of the Fable hospital are being adopted on ...
    ... motion in living cells may help researchers shed light ... according to Ning Fang, an associate scientist at the ... at Iowa State University. ... in Engineered Environments and Live Cells with Gold Nanorods ...
    ... shows that oncolytic viruses, which are engineered to destroy ... brain tumors if equipped with an enzyme that helps ... the cancer-killing virus clear its way through the thickets ... impede the virus,s movement through the tumor, say researchers ...
    ... -- Bottle rockets can cause serious eye injuries to children ... warns. Researchers at Vanderbilt University Medical Center in Nashville, ... aged 18 or younger, who suffered eye injuries caused by ... patients were injured while launching bottle rockets and two were ...
    Cached Medicine News:Health News:Population-wide reduction in salt consumption recommended 2Health News:Population-wide reduction in salt consumption recommended 3Health News:Giffords Opens Eyes. Like 'Watching a Miracle,' Friends Say 2Health News:Giffords Opens Eyes. Like 'Watching a Miracle,' Friends Say 3Health News:Next-generation hospital design can improve health -- and save money 2Health News:New tool for cell research may help unravel secrets of disease 2Health News:Virus might fight brain tumors better if armed with bacterial enzyme, study shows 2Health News:Bottle Rockets Can Cause Serious Eye Injuries in Kids 2
    ... The dual lumen petite ... 1.0 mm catheter (each lumen) ... Dual oval lumen catheters offer ... maximum catheter strength. Dual lumen ...
    Our smallest port is available with either a COOK Peel-Away or COOK Micropuncture Introducer Set....
    The standard-sized titanium port may be ordered with a silicone or polyurethane catheter. The silicone catheter is available with inner diameter sizes of 0.9, 1.0, 1.4, 1.6 mm. The polyurethane cathe...
    The WaveMap provides immediate clinical decision making information with automatic calculation of pressure gradients and FFR measurements.,SmartWire Pressure Guide Wire - The intelligent choice in ...
    Medicine Products: